<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;ff=20231129170803&amp;utm_medium=rss&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;v=2.17.9.post6+86293ac&amp;utm_campaign=pubmed-2
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;ff=20231129170803&amp;utm_medium=rss&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;v=2.17.9.post6+86293ac&amp;utm_campaign=pubmed-2" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.17.9.post6+86293ac)</generator>
<language>en</language>
<lastbuilddate>Wed, 29 Nov 2023 22:08:04 +0000</lastbuilddate>
<pubDate>Wed, 29 Nov 2023 06:00:00 -0500</pubDate>
<ttl>120</ttl>
<item>
<title>Can Noncalcified Plaques Contribute to Future Coronary Events?-Reply</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38019524/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231129170803&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Nov 29. doi: 10.1001/jamacardio.2023.4393. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38019524/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231129170803&v=2.17.9.post6+86293ac">38019524</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.4393>10.1001/jamacardio.2023.4393</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38019524</guid>
<pubDate>Wed, 29 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Alastair J Moss</dc:creator>
<dc:creator>Michelle C Williams</dc:creator>
<dc:creator>David E Newby</dc:creator>
<dc:date>2023-11-29</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Can Noncalcified Plaques Contribute to Future Coronary Events?-Reply</dc:title>
<dc:identifier>pmid:38019524</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.4393</dc:identifier>
</item>
<item>
<title>Pulsed Field Ablation-Will Coronary Spasm Lead to Iconoclasm?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38019506/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231129170803&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Nov 29. doi: 10.1001/jamacardio.2023.4441. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38019506/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231129170803&v=2.17.9.post6+86293ac">38019506</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.4441>10.1001/jamacardio.2023.4441</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38019506</guid>
<pubDate>Wed, 29 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Bradley P Knight</dc:creator>
<dc:creator>Anna Pfenniger</dc:creator>
<dc:date>2023-11-29</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Pulsed Field Ablation-Will Coronary Spasm Lead to Iconoclasm?</dc:title>
<dc:identifier>pmid:38019506</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.4441</dc:identifier>
</item>
<item>
<title>Coronary Artery Spasm During Pulsed Field vs Radiofrequency Catheter Ablation of the Mitral Isthmus</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38019505/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231129170803&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSION AND RELEVANCE: When creating a mitral isthmus ablation line during catheter ablation of atrial fibrillation, adjacent left circumflex arterial vasospasm frequently occurred with PFA and not RFA but was typically subclinical.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Nov 29. doi: 10.1001/jamacardio.2023.4405. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: In treating atrial fibrillation, pulsed field ablation (PFA) is a novel energy modality with comparable efficacy to conventional thermal ablation, such as radiofrequency ablation (RFA), but with the benefit of some preferentiality to myocardial tissue ablation. Studies have demonstrated important safety advantages, including the absence of esophageal injury or pulmonary vein stenosis and only rare phrenic nerve injury. However, there is emerging evidence of coronary artery vasospasm provoked by PFA.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To compare the incidence and severity of left circumflex arterial vasospasm between PFA and RFA during adjacent ablation along the mitral isthmus.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This prospective cohort study enrolled consecutive adult patients receiving first-ever PFA or RFA of the mitral isthmus during catheter ablation of atrial fibrillation in 2022 with acute follow-up at a single referral European center.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">EXPOSURE: A posterolateral mitral isthmus line was created using either a multielectrode pentaspline PFA catheter (endocardial ablation) or a saline-irrigated RFA catheter. Simultaneous diagnostic coronary angiography was performed before, during, and after catheter ablation. Nitroglycerin was planned for spasm persisting beyond 20 minutes or for significant electrocardiographic changes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: The frequency and severity of left circumflex arterial vasospasm was assessed and monitored, as were time to remission and any need for nitroglycerin administration.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Of 26 included patients, 19 (73%) were male, and the mean (SD) age was 65.5 (9.3) years. Patients underwent either PFA (n = 17) or RFA (n = 9) along the mitral isthmus. Coronary spasm was observed in 7 of 17 patients (41.2%) undergoing PFA: in 7 of 9 (77.8%) when the mitral isthmus ablation line was situated superiorly and in 0 of 8 when situated inferiorly. Conversely, coronary spasm did not occur in any of the 9 patients undergoing RFA. Of 5 patients in whom crossover PFA was performed after RFA failed to achieve conduction block, coronary spasm occurred in 3 (60%). Most instances of spasm (9 of 10 [90%]) were subclinical, with 2 (20%) requiring nitroglycerin administration. The median (range) time to resolution of spasm was 5 (5-25) minutes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSION AND RELEVANCE: When creating a mitral isthmus ablation line during catheter ablation of atrial fibrillation, adjacent left circumflex arterial vasospasm frequently occurred with PFA and not RFA but was typically subclinical.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38019505/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231129170803&v=2.17.9.post6+86293ac">38019505</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.4405>10.1001/jamacardio.2023.4405</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38019505</guid>
<pubDate>Wed, 29 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Chi Zhang</dc:creator>
<dc:creator>Petr Neuzil</dc:creator>
<dc:creator>Jan Petru</dc:creator>
<dc:creator>Moritoshi Funasako</dc:creator>
<dc:creator>Pavel Hala</dc:creator>
<dc:creator>Karel Kopriva</dc:creator>
<dc:creator>Jacob S Koruth</dc:creator>
<dc:creator>Srinivas R Dukkipati</dc:creator>
<dc:creator>Vivek Y Reddy</dc:creator>
<dc:date>2023-11-29</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Coronary Artery Spasm During Pulsed Field vs Radiofrequency Catheter Ablation of the Mitral Isthmus</dc:title>
<dc:identifier>pmid:38019505</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.4405</dc:identifier>
</item>
<item>
<title>Can Noncalcified Plaques Contribute to Future Coronary Events?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38019491/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231129170803&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Nov 29. doi: 10.1001/jamacardio.2023.4390. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38019491/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231129170803&v=2.17.9.post6+86293ac">38019491</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.4390>10.1001/jamacardio.2023.4390</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38019491</guid>
<pubDate>Wed, 29 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Muhammed I Erbay</dc:creator>
<dc:creator>Shriraj Susarla</dc:creator>
<dc:creator>Matthew J Budoff</dc:creator>
<dc:date>2023-11-29</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Can Noncalcified Plaques Contribute to Future Coronary Events?</dc:title>
<dc:identifier>pmid:38019491</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.4390</dc:identifier>
</item>
<item>
<title>Shedding the optical coherence tomography light on the treatment of complex coronary bifurcation lesions</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38018660/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231129170803&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Nov 29:ehad790. doi: 10.1093/eurheartj/ehad790. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38018660/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231129170803&v=2.17.9.post6+86293ac">38018660</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad790>10.1093/eurheartj/ehad790</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38018660</guid>
<pubDate>Wed, 29 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Rocco Vergallo</dc:creator>
<dc:creator>Leonarda Galiuto</dc:creator>
<dc:date>2023-11-29</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Shedding the optical coherence tomography light on the treatment of complex coronary bifurcation lesions</dc:title>
<dc:identifier>pmid:38018660</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad790</dc:identifier>
</item>
<item>
<title>Ganglioside GM3 Protects Against Abdominal Aortic Aneurysm by Suppressing Ferroptosis in Vascular Smooth Muscle Cells</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38018467/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231129170803&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Together, these results suggest that GM3 dysregulation promotes ferroptosis of vascular SMCs in AAA. Furthermore, GM3 may constitute a new therapeutic target for AAA.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Nov 29. doi: 10.1161/CIRCULATIONAHA.123.066110. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Abdominal aortic aneurysm (AAA) is a potentially life-threatening vascular condition, but approved medical therapies to prevent AAA progression and rupture are currently lacking. Sphingolipid metabolism disorders are associated with the occurrence and development of AAA. It has been discovered that ganglioside GM3, a sialic acid-containing type of glycosphingolipid, plays a protective role in atherosclerosis, which is an important risk factor for AAA; however, the potential contribution of GM3 to AAA development has not been investigated.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We performed a metabolomics study to evaluated GM3 level in plasma of human patients with AAA. We profiled GM3 synthase (ST3GAL5) expression in the mouse model of aneurysm and human AAA tissues through Western blotting and immunofluorescence staining. RNA sequencing, affinity purification and mass spectrometry, proteomic analysis, surface plasmon resonance analysis, and functional studies were used to dissect the molecular mechanism of GM3-regulating ferroptosis. We conditionally deleted and overexpressed <i>St3gal5</i> in smooth muscle cells (SMCs) in vivo to investigate its role in AAA.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: We found significantly reduced plasma levels of GM3 in human patients with AAA. GM3 content and ST3GAL5 expression were decreased in abdominal aortic vascular SMCs in patients with AAA and an AAA mouse model. RNA sequencing analysis showed that <i>ST3GAL5</i> silencing in human aortic SMCs induced ferroptosis. We showed that GM3 interacted directly with the extracellular domain of TFR1 (transferrin receptor 1), a cell membrane protein critical for cellular iron uptake, and disrupted its interaction with holo-transferrin. SMC-specific <i>St3gal5</i> knockout exacerbated iron accumulation at lesion sites and significantly promoted AAA development in mice, whereas GM3 supplementation suppressed lipid peroxidation, reduced iron deposition in aortic vascular SMCs, and markedly decreased AAA incidence.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Together, these results suggest that GM3 dysregulation promotes ferroptosis of vascular SMCs in AAA. Furthermore, GM3 may constitute a new therapeutic target for AAA.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38018467/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231129170803&v=2.17.9.post6+86293ac">38018467</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066110>10.1161/CIRCULATIONAHA.123.066110</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38018467</guid>
<pubDate>Wed, 29 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Fangni Zhang</dc:creator>
<dc:creator>Kan Li</dc:creator>
<dc:creator>Wenhui Zhang</dc:creator>
<dc:creator>Ziyan Zhao</dc:creator>
<dc:creator>Fangyuan Chang</dc:creator>
<dc:creator>Jie Du</dc:creator>
<dc:creator>Xu Zhang</dc:creator>
<dc:creator>Kaiwen Bao</dc:creator>
<dc:creator>Chunyong Zhang</dc:creator>
<dc:creator>Lei Shi</dc:creator>
<dc:creator>Zongwei Liu</dc:creator>
<dc:creator>Xiangchen Dai</dc:creator>
<dc:creator>Chen Chen</dc:creator>
<dc:creator>Dao Wen Wang</dc:creator>
<dc:creator>Zhong Xian</dc:creator>
<dc:creator>Hongfeng Jiang</dc:creator>
<dc:creator>Ding Ai</dc:creator>
<dc:date>2023-11-29</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Ganglioside GM3 Protects Against Abdominal Aortic Aneurysm by Suppressing Ferroptosis in Vascular Smooth Muscle Cells</dc:title>
<dc:identifier>pmid:38018467</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.066110</dc:identifier>
</item>
<item>
<title>Extracellular Matrix Disorganization Caused by ADAMTS16 Deficiency Leads to Bicuspid Aortic Valve With Raphe Formation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38018454/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231129170803&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Our present study identified a novel BAV-causing ADAMTS16 p. H357Q variant. ADAMTS16 deficiency led to BAV formation.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Nov 29. doi: 10.1161/CIRCULATIONAHA.123.065458. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: A better understanding of the molecular mechanism of aortic valve development and bicuspid aortic valve (BAV) formation would significantly improve and optimize the therapeutic strategy for BAV treatment. Over the past decade, the genes involved in aortic valve development and BAV formation have been increasingly recognized. On the other hand, a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS) gene family members have been reported to be able to modulate cardiovascular development and diseases. The present study aimed to further investigate the roles of ADAMTS family members in aortic valve development and BAV formation.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Morpholino-based ADAMTS family gene-targeted screening for zebrafish heart outflow tract phenotypes combined with DNA sequencing in a 304 cohort BAV patient registry study was initially carried out to identify potentially related genes. Both ADAMTS gene-specific fluorescence in situ hybridization assay and genetic tracing experiments were performed to evaluate the expression pattern in the aortic valve. Accordingly, related genetic mouse models (both knockout and knockin) were generated using the CRISPR/Cas9 method to further study the roles of ADAMTS family genes. The lineage-tracing technique was used again to evaluate how the cellular activity of specific progenitor cells was regulated by ADAMTS genes. Bulk RNA sequencing was used to investigate the signaling pathways involved. Inducible pluripotent stem cells derived from both BAV patients and genetic mouse tissue were used to study the molecular mechanism of ADAMTS. Immunohistochemistry was performed to examine the phenotype of cardiac valve anomalies, especially in the ECM components.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: ADAMTS genes targeting and phenotype screening in zebrafish and targeted DNA sequencing on a cohort of patients with BAV identified <i>ADAMTS16</i> as a BAV-causing gene and found the <i>ADAMTS16</i> p. H357Q variant in an inherited BAV family. Both in situ hybridization and genetic tracing studies described a unique spatiotemporal pattern of ADAMTS16 expression during aortic valve development. <i>Adamts16</i><sup><i>+/</i>-</sup> and <i>Adamts16</i><sup><i>+/H355Q</i></sup> mouse models both exhibited a right coronary cusp-noncoronary cusp fusion-type BAV phenotype, with progressive aortic valve thickening associated with raphe formation (fusion of the commissure). Further, ADAMTS16 deficiency in Tie2 lineage cells recapitulated the BAV phenotype. This was confirmed in lineage-tracing mouse models in which <i>Adamts16</i> deficiency affected endothelial and second heart field cells, not the neural crest cells. Accordingly, the changes were mainly detected in the noncoronary and right coronary leaflets. Bulk RNA sequencing using inducible pluripotent stem cells-derived endothelial cells and genetic mouse embryonic heart tissue unveiled enhanced FAK (focal adhesion kinase) signaling, which was accompanied by elevated fibronectin levels. Both in vitro inducible pluripotent stem cells-derived endothelial cells culture and ex vivo embryonic outflow tract explant studies validated the altered FAK signaling.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Our present study identified a novel BAV-causing <i>ADAMTS16</i> p. H357Q variant. ADAMTS16 deficiency led to BAV formation.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38018454/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231129170803&v=2.17.9.post6+86293ac">38018454</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065458>10.1161/CIRCULATIONAHA.123.065458</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38018454</guid>
<pubDate>Wed, 29 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Ying Lin</dc:creator>
<dc:creator>Qifan Yang</dc:creator>
<dc:creator>Xiaoping Lin</dc:creator>
<dc:creator>Xianbao Liu</dc:creator>
<dc:creator>Yi Qian</dc:creator>
<dc:creator>Dilin Xu</dc:creator>
<dc:creator>Naifang Cao</dc:creator>
<dc:creator>Ximeng Han</dc:creator>
<dc:creator>Yanqing Zhu</dc:creator>
<dc:creator>Wangxing Hu</dc:creator>
<dc:creator>Xiaopeng He</dc:creator>
<dc:creator>Zhengyang Yu</dc:creator>
<dc:creator>Xiangmin Kong</dc:creator>
<dc:creator>Lianlian Zhu</dc:creator>
<dc:creator>Zhiwei Zhong</dc:creator>
<dc:creator>Kai Liu</dc:creator>
<dc:creator>Bin Zhou</dc:creator>
<dc:creator>Yidong Wang</dc:creator>
<dc:creator>Jinrong Peng</dc:creator>
<dc:creator>Wei Zhu</dc:creator>
<dc:creator>Jian'an Wang</dc:creator>
<dc:date>2023-11-29</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Extracellular Matrix Disorganization Caused by ADAMTS16 Deficiency Leads to Bicuspid Aortic Valve With Raphe Formation</dc:title>
<dc:identifier>pmid:38018454</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.065458</dc:identifier>
</item>
<item>
<title>Flipped C-Terminal Ends of apoA1 Promote ABCA1-Dependent Cholesterol Efflux by Small HDLs</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38018436/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231129170803&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: We present a mechanism for the enhanced CEC of small HDLs. In smaller particles, the C-termini of the 2 antiparallel molecules of apoA1 are "flipped" off the lipid surface of HDL. This extended conformation allows them to engage with ABCA1. In contrast, the C-termini of larger HDLs are unable to interact productively with ABCA1 because they form a helical bundle that strongly adheres to the lipid on the particle. Enhanced CEC, as seen with the smaller particles, predicts decreased...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Nov 29. doi: 10.1161/CIRCULATIONAHA.123.065959. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Cholesterol efflux capacity (CEC) predicts cardiovascular disease independently of high-density lipoprotein (HDL) cholesterol levels. Isolated small HDL particles are potent promoters of macrophage CEC by the ABCA1 (ATP-binding cassette transporter A1) pathway, but the underlying mechanisms are unclear.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We used model system studies of reconstituted HDL and plasma from control and lecithin-cholesterol acyltransferase (LCAT)-deficient subjects to investigate the relationships among the sizes of HDL particles, the structure of apoA1 (apolipoprotein A1) in the different particles, and the CECs of plasma and isolated HDLs.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: We quantified macrophage and ABCA1 CEC of 4 distinct sizes of reconstituted HDL. CEC increased as particle size decreased. Tandem mass spectrometry analysis of chemically cross-linked peptides and molecular dynamics simulations of apoA1, the major protein of HDL, indicated that the mobility of C-terminus of that protein was markedly higher and flipped off the surface in the smallest particles. To explore the physiological relevance of the model system studies, we isolated HDL from LCAT-deficient subjects, the small HDLs (eg, reconstituted HDLs) of which are discoidal and composed of apoA1, cholesterol, and phospholipid. Despite their very low plasma levels of HDL particles, these subjects had normal CEC. In both the LCAT-deficient subjects and control subjects, the CEC of isolated extra-small HDL (a mixture of extra-small and small HDL by calibrated ion mobility analysis) was 3- to 5-fold greater than that of the larger sizes of isolated HDL. Incubating LCAT-deficient plasma and control plasma with human LCAT converted extra-small and small HDL particles into larger particles, and it markedly inhibited CEC.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: We present a mechanism for the enhanced CEC of small HDLs. In smaller particles, the C-termini of the 2 antiparallel molecules of apoA1 are "flipped" off the lipid surface of HDL. This extended conformation allows them to engage with ABCA1. In contrast, the C-termini of larger HDLs are unable to interact productively with ABCA1 because they form a helical bundle that strongly adheres to the lipid on the particle. Enhanced CEC, as seen with the smaller particles, predicts decreased cardiovascular disease risk. Thus, extra-small and small HDLs may be key mediators and indicators of the cardioprotective effects of HDL.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38018436/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231129170803&v=2.17.9.post6+86293ac">38018436</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065959>10.1161/CIRCULATIONAHA.123.065959</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38018436</guid>
<pubDate>Wed, 29 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Yi He</dc:creator>
<dc:creator>Chiara Pavanello</dc:creator>
<dc:creator>Patrick M Hutchins</dc:creator>
<dc:creator>Chongren Tang</dc:creator>
<dc:creator>Mohsen Pourmousa</dc:creator>
<dc:creator>Tomas Vaisar</dc:creator>
<dc:creator>Hyun D Song</dc:creator>
<dc:creator>Richard W Pastor</dc:creator>
<dc:creator>Alan T Remaley</dc:creator>
<dc:creator>Ira J Goldberg</dc:creator>
<dc:creator>Tina Costacou</dc:creator>
<dc:creator>W Sean Davidson</dc:creator>
<dc:creator>Karin E Bornfeldt</dc:creator>
<dc:creator>Laura Calabresi</dc:creator>
<dc:creator>Jere P Segrest</dc:creator>
<dc:creator>Jay W Heinecke</dc:creator>
<dc:date>2023-11-29</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Flipped C-Terminal Ends of apoA1 Promote ABCA1-Dependent Cholesterol Efflux by Small HDLs</dc:title>
<dc:identifier>pmid:38018436</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.065959</dc:identifier>
</item>
<item>
<title>Reactive Oxygen Species Modulator 1 (ROMO1) Plays an Obligate Role in Cardiomyocyte Hypertrophy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38018429/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231129170803&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2023 Nov 29. doi: 10.1161/CIRCRESAHA.123.323456. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38018429/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231129170803&v=2.17.9.post6+86293ac">38018429</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.323456>10.1161/CIRCRESAHA.123.323456</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38018429</guid>
<pubDate>Wed, 29 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Matthew D Martens</dc:creator>
<dc:creator>Claudia D Holody</dc:creator>
<dc:creator>Lisa Wells</dc:creator>
<dc:creator>Heidi L Silver</dc:creator>
<dc:creator>Daniela Y Morales-Llamas</dc:creator>
<dc:creator>William W Du</dc:creator>
<dc:creator>Courtney Reeks</dc:creator>
<dc:creator>Mostafa Khairy</dc:creator>
<dc:creator>Huachen Chen</dc:creator>
<dc:creator>Mourad Ferdaoussi</dc:creator>
<dc:creator>Stephane L Bourque</dc:creator>
<dc:creator>Burton B Yang</dc:creator>
<dc:creator>John R Ussher</dc:creator>
<dc:creator>Helene Lemieux</dc:creator>
<dc:creator>Gavin Y Oudit</dc:creator>
<dc:creator>Robert A Screaton</dc:creator>
<dc:creator>Jason R B Dyck</dc:creator>
<dc:date>2023-11-29</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Reactive Oxygen Species Modulator 1 (ROMO1) Plays an Obligate Role in Cardiomyocyte Hypertrophy</dc:title>
<dc:identifier>pmid:38018429</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.323456</dc:identifier>
</item>
<item>
<title>Self-monitoring strategy reduces postpartum hypertension and cardiac remodelling</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38017232/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231129170803&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2023 Nov 28. doi: 10.1038/s41569-023-00966-z. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38017232/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231129170803&v=2.17.9.post6+86293ac">38017232</a> | DOI:<a href=https://doi.org/10.1038/s41569-023-00966-z>10.1038/s41569-023-00966-z</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38017232</guid>
<pubDate>Tue, 28 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Karina Huynh</dc:creator>
<dc:date>2023-11-28</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Self-monitoring strategy reduces postpartum hypertension and cardiac remodelling</dc:title>
<dc:identifier>pmid:38017232</dc:identifier>
<dc:identifier>doi:10.1038/s41569-023-00966-z</dc:identifier>
</item>
<item>
<title>Prolonged sleep deprivation induces a cytokine-storm-like syndrome in mammals</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38016470/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231129170803&amp;v=2.17.9.post6+86293ac
      <description>Most animals require sleep, and sleep loss induces serious pathophysiological consequences, including death. Previous experimental approaches for investigating sleep impacts in mice have been unable to persistently deprive animals of both rapid eye movement sleep (REMS) and non-rapid eye movement sleep (NREMS). Here, we report a "curling prevention by water" paradigm wherein mice remain awake 96% of the time. After 4 days of exposure, mice exhibit severe inflammation, and approximately 80% die....</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2023 Nov 14:S0092-8674(23)01176-5. doi: 10.1016/j.cell.2023.10.025. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Most animals require sleep, and sleep loss induces serious pathophysiological consequences, including death. Previous experimental approaches for investigating sleep impacts in mice have been unable to persistently deprive animals of both rapid eye movement sleep (REMS) and non-rapid eye movement sleep (NREMS). Here, we report a "curling prevention by water" paradigm wherein mice remain awake 96% of the time. After 4 days of exposure, mice exhibit severe inflammation, and approximately 80% die. Sleep deprivation increases levels of prostaglandin D<sub>2</sub> (PGD<sub>2</sub>) in the brain, and we found that elevated PGD<sub>2</sub> efflux across the blood-brain-barrier-mediated by ATP-binding cassette subfamily C4 transporter-induces both accumulation of circulating neutrophils and a cytokine-storm-like syndrome. Experimental disruption of the PGD<sub>2</sub>/DP1 axis dramatically reduced sleep-deprivation-induced inflammation. Thus, our study reveals that sleep-related changes in PGD<sub>2</sub> in the central nervous system drive profound pathological consequences in the peripheral immune system.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38016470/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231129170803&v=2.17.9.post6+86293ac">38016470</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.10.025>10.1016/j.cell.2023.10.025</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38016470</guid>
<pubDate>Tue, 28 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Di Sang</dc:creator>
<dc:creator>Keteng Lin</dc:creator>
<dc:creator>Yini Yang</dc:creator>
<dc:creator>Guangdi Ran</dc:creator>
<dc:creator>Bohan Li</dc:creator>
<dc:creator>Chen Chen</dc:creator>
<dc:creator>Qi Li</dc:creator>
<dc:creator>Yan Ma</dc:creator>
<dc:creator>Lihui Lu</dc:creator>
<dc:creator>Xi-Yang Cui</dc:creator>
<dc:creator>Zhibo Liu</dc:creator>
<dc:creator>Sheng-Qing Lv</dc:creator>
<dc:creator>Minmin Luo</dc:creator>
<dc:creator>Qinghua Liu</dc:creator>
<dc:creator>Yulong Li</dc:creator>
<dc:creator>Eric Erquan Zhang</dc:creator>
<dc:date>2023-11-28</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Prolonged sleep deprivation induces a cytokine-storm-like syndrome in mammals</dc:title>
<dc:identifier>pmid:38016470</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.10.025</dc:identifier>
</item>
<item>
<title>TScan-II: A genome-scale platform for the de novo identification of CD4&lt;sup>;+&lt;/sup>; T cell epitopes</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38016469/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231129170803&amp;v=2.17.9.post6+86293ac
      <description>CD4^(+) T cells play fundamental roles in orchestrating immune responses and tissue homeostasis. However, our inability to associate peptide human leukocyte antigen class-II (HLA-II) complexes with their cognate T cell receptors (TCRs) in an unbiased manner has hampered our understanding of CD4^(+) T cell function and role in pathologies. Here, we introduce TScan-II, a highly sensitive genome-scale CD4^(+) antigen discovery platform. This platform seamlessly integrates the endogenous HLA-II...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2023 Nov 16:S0092-8674(23)01175-3. doi: 10.1016/j.cell.2023.10.024. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CD4<sup>+</sup> T cells play fundamental roles in orchestrating immune responses and tissue homeostasis. However, our inability to associate peptide human leukocyte antigen class-II (HLA-II) complexes with their cognate T cell receptors (TCRs) in an unbiased manner has hampered our understanding of CD4<sup>+</sup> T cell function and role in pathologies. Here, we introduce TScan-II, a highly sensitive genome-scale CD4<sup>+</sup> antigen discovery platform. This platform seamlessly integrates the endogenous HLA-II antigen-processing machinery in synthetic antigen-presenting cells and TCR signaling in T cells, enabling the simultaneous screening of multiple HLAs and TCRs. Leveraging genome-scale human, virome, and epitope mutagenesis libraries, TScan-II facilitates de novo antigen discovery and deep exploration of TCR specificity. We demonstrate TScan-II's potential for basic and translational research by identifying a non-canonical antigen for a cancer-reactive CD4<sup>+</sup> T cell clone. Additionally, we identified two antigens for clonally expanded CD4<sup>+</sup> T cells in Sjögren's disease, which bind distinct HLAs and are expressed in HLA-II-positive ductal cells within affected salivary glands.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38016469/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231129170803&v=2.17.9.post6+86293ac">38016469</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.10.024>10.1016/j.cell.2023.10.024</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38016469</guid>
<pubDate>Tue, 28 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Mohammad H Dezfulian</dc:creator>
<dc:creator>Tomasz Kula</dc:creator>
<dc:creator>Thomas Pranzatelli</dc:creator>
<dc:creator>Nolan Kamitaki</dc:creator>
<dc:creator>Qingda Meng</dc:creator>
<dc:creator>Bhuwan Khatri</dc:creator>
<dc:creator>Paola Perez</dc:creator>
<dc:creator>Qikai Xu</dc:creator>
<dc:creator>Aiquan Chang</dc:creator>
<dc:creator>Ayano C Kohlgruber</dc:creator>
<dc:creator>Yumei Leng</dc:creator>
<dc:creator>Ananth Aditya Jupudi</dc:creator>
<dc:creator>Michelle L Joachims</dc:creator>
<dc:creator>John A Chiorini</dc:creator>
<dc:creator>Christopher J Lessard</dc:creator>
<dc:creator>A Darise Farris</dc:creator>
<dc:creator>Senthil K Muthuswamy</dc:creator>
<dc:creator>Blake M Warner</dc:creator>
<dc:creator>Stephen J Elledge</dc:creator>
<dc:date>2023-11-28</dc:date>
<dc:source>Cell</dc:source>
<dc:title>TScan-II: A genome-scale platform for the de novo identification of CD4&lt;sup>;+&lt;/sup>; T cell epitopes</dc:title>
<dc:identifier>pmid:38016469</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.10.024</dc:identifier>
</item>
<item>
<title>Optical coherence tomography to guide percutaneous coronary intervention: is the glass half full or half empty?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38015998/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231129170803&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Nov 28:ehad792. doi: 10.1093/eurheartj/ehad792. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38015998/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231129170803&v=2.17.9.post6+86293ac">38015998</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad792>10.1093/eurheartj/ehad792</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38015998</guid>
<pubDate>Tue, 28 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Rocco Vergallo</dc:creator>
<dc:creator>Massimo Volpe</dc:creator>
<dc:date>2023-11-28</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Optical coherence tomography to guide percutaneous coronary intervention: is the glass half full or half empty?</dc:title>
<dc:identifier>pmid:38015998</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad792</dc:identifier>
</item>
<item>
<title>Atrial fibrillation first detected after stroke: is timing and detection intensity relevant for stroke risk?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38014646/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231129170803&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Nov 28:ehad744. doi: 10.1093/eurheartj/ehad744. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38014646/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231129170803&v=2.17.9.post6+86293ac">38014646</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad744>10.1093/eurheartj/ehad744</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38014646</guid>
<pubDate>Tue, 28 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Luciano A Sposato</dc:creator>
<dc:creator>Gregory Y H Lip</dc:creator>
<dc:creator>Karl Georg Haeusler</dc:creator>
<dc:date>2023-11-28</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Atrial fibrillation first detected after stroke: is timing and detection intensity relevant for stroke risk?</dc:title>
<dc:identifier>pmid:38014646</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad744</dc:identifier>
</item>
<item>
<title>Childhood Non-HDL Cholesterol and LDL Cholesterol and Adult Atherosclerotic Cardiovascular Events</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38014550/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231129170803&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Childhood non-HDL-C and LDL-C levels are associated with ASCVD events in midlife. Non-HDL-C is better than LDL-C in predicting adult ASCVD events, particularly among individuals who had normal LDL-C but elevated non-HDL-C. These findings suggest that both non-HDL-C and LDL-C are useful in identifying children at higher risk of ASCVD events, but non-HDL-C may provide added prognostic information when it is discordantly higher than the corresponding LDL-C and has the practical...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Nov 28. doi: 10.1161/CIRCULATIONAHA.123.064296. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Although low-density lipoprotein cholesterol (LDL-C) remains the primary cholesterol target in clinical practice in children and adults, non-high-density lipoprotein cholesterol (non-HDL-C) has been suggested as a more accurate measure of atherosclerotic cardiovascular disease (ASCVD) risk. We examined the associations of childhood non-HDL-C and LDL-C levels with adult ASCVD events and determined whether non-HDL-C has better utility than LDL-C in predicting adult ASCVD events.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: This prospective cohort study included 21 126 participants from the i3C Consortium (International Childhood Cardiovascular Cohorts). Proportional hazards regressions were used to estimate the risk for incident fatal and fatal/nonfatal ASCVD events associated with childhood non-HDL-C and LDL-C levels (age- and sex-specific <i>z</i> scores; concordant/discordant categories defined by guideline-recommended cutoffs), adjusted for sex, Black race, cohort, age at and calendar year of child measurement, body mass index, and systolic blood pressure. Predictive utility was determined by the C index.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: After an average follow-up of 35 years, 153 fatal ASCVD events occurred in 21 126 participants (mean age at childhood visits, 11.9 years), and 352 fatal/nonfatal ASCVD events occurred in a subset of 11 296 participants who could be evaluated for this outcome. Childhood non-HDL-C and LDL-C levels were each associated with higher risk of fatal and fatal/nonfatal ASCVD events (hazard ratio ranged from 1.27 [95% CI, 1.14-1.41] to 1.35 [95% CI, 1.13-1.60] per unit increase in the risk factor <i>z</i> score). Non-HDL-C had better discriminative utility than LDL-C (difference in C index, 0.0054 [95% CI, 0.0006-0.0102] and 0.0038 [95% CI, 0.0008-0.0068] for fatal and fatal/nonfatal events, respectively). The discordant group with elevated non-HDL-C and normal LDL-C had a higher risk of ASCVD events compared with the concordant group with normal non-HDL-C and LDL-C (fatal events: hazard ratio, 1.90 [95% CI, 0.98-3.70]; fatal/nonfatal events: hazard ratio, 1.94 [95% CI, 1.23-3.06]).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Childhood non-HDL-C and LDL-C levels are associated with ASCVD events in midlife. Non-HDL-C is better than LDL-C in predicting adult ASCVD events, particularly among individuals who had normal LDL-C but elevated non-HDL-C. These findings suggest that both non-HDL-C and LDL-C are useful in identifying children at higher risk of ASCVD events, but non-HDL-C may provide added prognostic information when it is discordantly higher than the corresponding LDL-C and has the practical advantage of being determined without a fasting sample.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38014550/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231129170803&v=2.17.9.post6+86293ac">38014550</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.064296>10.1161/CIRCULATIONAHA.123.064296</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38014550</guid>
<pubDate>Tue, 28 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Feitong Wu</dc:creator>
<dc:creator>Markus Juonala</dc:creator>
<dc:creator>David R Jacobs</dc:creator>
<dc:creator>Stephen R Daniels</dc:creator>
<dc:creator>Mika Kähönen</dc:creator>
<dc:creator>Jessica G Woo</dc:creator>
<dc:creator>Alan R Sinaiko</dc:creator>
<dc:creator>Jorma S A Viikari</dc:creator>
<dc:creator>Lydia A Bazzano</dc:creator>
<dc:creator>Trudy L Burns</dc:creator>
<dc:creator>Julia Steinberger</dc:creator>
<dc:creator>Elaine M Urbina</dc:creator>
<dc:creator>Alison J Venn</dc:creator>
<dc:creator>Olli T Raitakari</dc:creator>
<dc:creator>Terence Dwyer</dc:creator>
<dc:creator>Costan G Magnussen</dc:creator>
<dc:date>2023-11-28</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Childhood Non-HDL Cholesterol and LDL Cholesterol and Adult Atherosclerotic Cardiovascular Events</dc:title>
<dc:identifier>pmid:38014550</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.064296</dc:identifier>
</item>
<item>
<title>Critical Care Management of Patients After Cardiac Arrest: A Scientific Statement From the American Heart Association and Neurocritical Care Society</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38014539/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231129170803&amp;v=2.17.9.post6+86293ac
      <description>The critical care management of patients after cardiac arrest is burdened by a lack of high-quality clinical studies and the resultant lack of high-certainty evidence. This results in limited practice guideline recommendations, which may lead to uncertainty and variability in management. Critical care management is crucial in patients after cardiac arrest and affects outcome. Although guidelines address some relevant topics (including temperature control and neurological prognostication of...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Nov 28. doi: 10.1161/CIR.0000000000001163. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The critical care management of patients after cardiac arrest is burdened by a lack of high-quality clinical studies and the resultant lack of high-certainty evidence. This results in limited practice guideline recommendations, which may lead to uncertainty and variability in management. Critical care management is crucial in patients after cardiac arrest and affects outcome. Although guidelines address some relevant topics (including temperature control and neurological prognostication of comatose survivors, 2 topics for which there are more robust clinical studies), many important subject areas have limited or nonexistent clinical studies, leading to the absence of guidelines or low-certainty evidence. The American Heart Association Emergency Cardiovascular Care Committee and the Neurocritical Care Society collaborated to address this gap by organizing an expert consensus panel and conference. Twenty-four experienced practitioners (including physicians, nurses, pharmacists, and a respiratory therapist) from multiple medical specialties, levels, institutions, and countries made up the panel. Topics were identified and prioritized by the panel and arranged by organ system to facilitate discussion, debate, and consensus building. Statements related to postarrest management were generated, and 80% agreement was required to approve a statement. Voting was anonymous and web based. Topics addressed include neurological, cardiac, pulmonary, hematological, infectious, gastrointestinal, endocrine, and general critical care management. Areas of uncertainty, areas for which no consensus was reached, and future research directions are also included. Until high-quality studies that inform practice guidelines in these areas are available, the expert panel consensus statements that are provided can advise clinicians on the critical care management of patients after cardiac arrest.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38014539/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231129170803&v=2.17.9.post6+86293ac">38014539</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001163>10.1161/CIR.0000000000001163</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38014539</guid>
<pubDate>Tue, 28 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Karen G Hirsch</dc:creator>
<dc:creator>Benjamin S Abella</dc:creator>
<dc:creator>Edilberto Amorim</dc:creator>
<dc:creator>Mary Kay Bader</dc:creator>
<dc:creator>Jeffrey F Barletta</dc:creator>
<dc:creator>Katherine Berg</dc:creator>
<dc:creator>Clifton W Callaway</dc:creator>
<dc:creator>Hans Friberg</dc:creator>
<dc:creator>Emily J Gilmore</dc:creator>
<dc:creator>David M Greer</dc:creator>
<dc:creator>Karl B Kern</dc:creator>
<dc:creator>Sarah Livesay</dc:creator>
<dc:creator>Teresa L May</dc:creator>
<dc:creator>Robert W Neumar</dc:creator>
<dc:creator>Jerry P Nolan</dc:creator>
<dc:creator>Mauro Oddo</dc:creator>
<dc:creator>Mary Ann Peberdy</dc:creator>
<dc:creator>Samuel M Poloyac</dc:creator>
<dc:creator>David Seder</dc:creator>
<dc:creator>Fabio Silvio Taccone</dc:creator>
<dc:creator>Anezi Uzendu</dc:creator>
<dc:creator>Brian Walsh</dc:creator>
<dc:creator>Janice L Zimmerman</dc:creator>
<dc:creator>Romergryko G Geocadin</dc:creator>
<dc:creator>American Heart Association and Neurocritical Care Society</dc:creator>
<dc:date>2023-11-28</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Critical Care Management of Patients After Cardiac Arrest: A Scientific Statement From the American Heart Association and Neurocritical Care Society</dc:title>
<dc:identifier>pmid:38014539</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001163</dc:identifier>
</item>
<item>
<title>Aspirin exclusion in patients with an LVAD</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38012304/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231129170803&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2023 Nov 27. doi: 10.1038/s41569-023-00965-0. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38012304/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231129170803&v=2.17.9.post6+86293ac">38012304</a> | DOI:<a href=https://doi.org/10.1038/s41569-023-00965-0>10.1038/s41569-023-00965-0</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38012304</guid>
<pubDate>Mon, 27 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Gregory B Lim</dc:creator>
<dc:date>2023-11-27</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Aspirin exclusion in patients with an LVAD</dc:title>
<dc:identifier>pmid:38012304</dc:identifier>
<dc:identifier>doi:10.1038/s41569-023-00965-0</dc:identifier>
</item>
<item>
<title>Expanding the Definition of Worsening Heart Failure and Recognizing the Importance of Outpatient Escalation of Oral Diuretics</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38011247/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231129170803&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Nov 28;148(22):1746-1749. doi: 10.1161/CIRCULATIONAHA.123.066915. Epub 2023 Nov 27.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38011247/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231129170803&v=2.17.9.post6+86293ac">38011247</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066915>10.1161/CIRCULATIONAHA.123.066915</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38011247</guid>
<pubDate>Mon, 27 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Stephen J Greene</dc:creator>
<dc:creator>Javed Butler</dc:creator>
<dc:date>2023-11-27</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Expanding the Definition of Worsening Heart Failure and Recognizing the Importance of Outpatient Escalation of Oral Diuretics</dc:title>
<dc:identifier>pmid:38011247</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.066915</dc:identifier>
</item>
<item>
<title>Making the Right Diagnosis: Slowly but Surely</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38011246/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231129170803&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Nov 28;148(22):1814-1818. doi: 10.1161/CIRCULATIONAHA.123.067074. Epub 2023 Nov 27.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38011246/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231129170803&v=2.17.9.post6+86293ac">38011246</a> | PMC:<a href="https://www.ncbi.nlm.nih.gov/pmc/PMC10664777/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231129170803&v=2.17.9.post6+86293ac">PMC10664777</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067074>10.1161/CIRCULATIONAHA.123.067074</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38011246</guid>
<pubDate>Mon, 27 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Parag R Gajendragadkar</dc:creator>
<dc:creator>Claire A Martin</dc:creator>
<dc:creator>Rohan S Wijesurendra</dc:creator>
<dc:date>2023-11-27</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Making the Right Diagnosis: Slowly but Surely</dc:title>
<dc:identifier>pmid:38011246</dc:identifier>
<dc:identifier>pmc:PMC10664777</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.067074</dc:identifier>
</item>
<item>
<title>Evolving Contemporary Management of Atrial Fibrillation in Hypertrophic Cardiomyopathy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38011245/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231129170803&amp;v=2.17.9.post6+86293ac
      <description>Atrial fibrillation (AF) is the most common sustained arrhythmia in hypertrophic cardiomyopathy (HCM) with clinical and subclinical episodes occurring in nearly one-half of patients. AF in HCM historically has been characterized as a decisive disease complication associated with substantial risk for thromboembolic stroke and increased morbidity and mortality. However, there have been many advances in treatment strategy resulting in improved outcomes for this patient group. For example, stroke...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Nov 28;148(22):1797-1811. doi: 10.1161/CIRCULATIONAHA.123.065037. Epub 2023 Nov 27.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Atrial fibrillation (AF) is the most common sustained arrhythmia in hypertrophic cardiomyopathy (HCM) with clinical and subclinical episodes occurring in nearly one-half of patients. AF in HCM historically has been characterized as a decisive disease complication associated with substantial risk for thromboembolic stroke and increased morbidity and mortality. However, there have been many advances in treatment strategy resulting in improved outcomes for this patient group. For example, stroke risk in HCM has been greatly reduced by using systemic oral anticoagulation initiated after the first clinical (symptomatic) AF episode, usually with preference given to direct anticoagulants over warfarin. In contrast, stroke risk scoring systems (such as CHA<sub>2</sub>DS<sub>2</sub>-VASc score) are not informative in HCM given the substantial potential for stroke events in patients with low scores, and therefore should not be used for anticoagulation decisions in this disease. A novel risk score specifically designed for HCM (HCM-AF score) can reliably identify most patients with HCM at risk for future AF. Although a strategy focused on controlling ventricular rate is effective in asymptomatic (or minimally symptomatic) patients with AF, restoring and maintaining sinus rhythm is required for most patients with marked AF symptom burden and impaired quality of life. Several antiarrhythmic drugs such as sotalol, disopyramide, and amiodarone, can be effective in suppressing AF episodes; albeit safe, long-term efficacy is supported by only limited data. Catheter AF ablation has emerged as an important treatment option for some patients, although freedom from AF after a single ablation is relatively low (35% at 3 years), multiple ablations and the concomitant use of antiarrhythmic drugs can control AF with more than two-thirds of patients maintaining sinus rhythm at 5 years. Surgical AF ablation with biatrial Cox-Maze IV performed as an adjunctive procedure during myectomy can reduce symptomatic AF episodes (70% of patients free from AF at 5 years). For the vast majority of patients who have HCM with AF, the implementation of contemporary therapies has allowed for improved quality of life and low HCM-related mortality.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38011245/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231129170803&v=2.17.9.post6+86293ac">38011245</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065037>10.1161/CIRCULATIONAHA.123.065037</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38011245</guid>
<pubDate>Mon, 27 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Ethan J Rowin</dc:creator>
<dc:creator>Mark S Link</dc:creator>
<dc:creator>Martin S Maron</dc:creator>
<dc:creator>Barry J Maron</dc:creator>
<dc:date>2023-11-27</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Evolving Contemporary Management of Atrial Fibrillation in Hypertrophic Cardiomyopathy</dc:title>
<dc:identifier>pmid:38011245</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.065037</dc:identifier>
</item>
<item>
<title>Epitranscriptomic Modification of MicroRNA Increases Atherosclerosis Susceptibility</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38011244/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231129170803&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Nov 28;148(22):1819-1822. doi: 10.1161/CIRCULATIONAHA.123.065455. Epub 2023 Nov 27.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38011244/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231129170803&v=2.17.9.post6+86293ac">38011244</a> | PMC:<a href="https://www.ncbi.nlm.nih.gov/pmc/PMC10683863/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231129170803&v=2.17.9.post6+86293ac">PMC10683863</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065455>10.1161/CIRCULATIONAHA.123.065455</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38011244</guid>
<pubDate>Mon, 27 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Ming He</dc:creator>
<dc:creator>Jianjie Dong</dc:creator>
<dc:creator>Junmao Wen</dc:creator>
<dc:creator>Yuqing Zhang</dc:creator>
<dc:creator>So Yun Han</dc:creator>
<dc:creator>Chen Wang</dc:creator>
<dc:creator>Brendan Gongol</dc:creator>
<dc:creator>Tong-You Wade Wei</dc:creator>
<dc:creator>Jian Kang</dc:creator>
<dc:creator>Hsi-Yuan Huang</dc:creator>
<dc:creator>Susan Cheng</dc:creator>
<dc:creator>John Y-J Shyy</dc:creator>
<dc:date>2023-11-27</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Epitranscriptomic Modification of MicroRNA Increases Atherosclerosis Susceptibility</dc:title>
<dc:identifier>pmid:38011244</dc:identifier>
<dc:identifier>pmc:PMC10683863</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.065455</dc:identifier>
</item>





























</channel>
</rss>